IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
63.55
-0.20 (-0.31%)
Apr 2, 2025, 3:29 PM IST
NSE:IOLCP Revenue
IOL Chemicals and Pharmaceuticals had revenue of 5.23B INR in the quarter ending December 31, 2024, with 0.56% growth. This brings the company's revenue in the last twelve months to 20.55B, down -7.25% year-over-year. In the fiscal year ending March 31, 2024, IOL Chemicals and Pharmaceuticals had annual revenue of 21.33B, down -3.80%.
Revenue (ttm)
20.55B
Revenue Growth
-7.25%
P/S Ratio
n/a
Revenue / Employee
7.40M
Employees
2,777
Market Cap
18.61B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 21.33B | -843.20M | -3.80% |
Mar 31, 2023 | 22.17B | 330.90M | 1.52% |
Mar 31, 2022 | 21.84B | 2.17B | 11.03% |
Mar 31, 2021 | 19.67B | 725.10M | 3.83% |
Mar 31, 2020 | 18.94B | 2.09B | 12.41% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
IOL Chemicals and Pharmaceuticals News
- 27 days ago - IOL Chemicals shares surge 4% after EDQM certification for Quetiapine Fumarate - Business Upturn
- 3 months ago - IOL Chemicals and Pharmaceuticals shares rise nearly 4% as board approves 1:5 stock split - Business Upturn
- 3 months ago - IOL Chemicals shares surge 7% after company plans to consider stock split - Business Upturn
- 4 months ago - IOL Chemicals & Pharmaceuticals shares fall nearly 5% after disappointing Q2 FY25 results - Business Upturn